Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2021-04-23 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
中源协和细胞基因工程股份有限公司关于计提资产减值损失的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors regarding the company's decision to recognize asset impairment losses for the fiscal year ending December 31, 2020. It details the amounts of impairment losses on receivables, goodwill, and inventory, and explains the impact on net profit. The document includes statements from the board, independent directors, and the audit committee supporting the impairment recognition. The document is relatively short (1823 characters) and focuses on a specific accounting event rather than presenting a full financial report or audit report. It is not a full Annual Report (10-K), Interim Report (IR), or Audit Report (AR), but rather a regulatory announcement about the impairment loss recognition. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2021-04-23 Chinese
中源协和细胞基因工程股份有限公司关于下属子公司收到政府补助资金的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (498 characters) regarding a government subsidy received by a subsidiary of the company. It includes details about the subsidy type and its accounting treatment but does not contain comprehensive financial statements or detailed financial analysis. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR). It is also not a certification or officer attestation. The document is an official announcement about a specific financial event (government subsidy) impacting the company. Given its brevity and content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-02-26 Chinese
中源协和细胞基因工程股份有限公司关于下属子公司收到政府补助资金的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding government subsidies received by its subsidiaries. It details the amounts, accounting treatment, and impact on the company. There is no indication of it being a full financial report, audit report, or earnings release. It is a regulatory announcement about a specific financial event (government grants) affecting the company. The document length is short (1704 characters), and it is not a report publication announcement or certification. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-02-25 Chinese
2020年年度业绩预亏公告
Regulatory Filings Classification · 95% confidence The document is a 2020 annual performance forecast announcement by Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It provides preliminary estimated net profit losses for the year 2020 and explains the reasons for the expected loss, including goodwill impairment. The document explicitly states that the forecast data is preliminary and unaudited, and the final audited data will be disclosed in the formal 2020 annual report. The document length is short (948 characters) and it serves as an announcement of expected financial results rather than a full financial report. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of performance forecast, not the full Annual Report (10-K) or Earnings Release (ER) which would contain actual audited financial data or key highlights respectively. The document does not fit the definition of an Earnings Release since it is a forecast and not an initial announcement of quarterly or periodical results. Hence, the classification is RNS with high confidence.
2021-01-27 Chinese
副董事长辞职公告
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding the resignation of the company's Vice Chairman and other board positions. It details the resignation date, the impact on the board, and expresses gratitude for the individual's contributions. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to shareholder votes or meetings. The content clearly relates to changes in the company's board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short but contains substantive information about management changes, not just a brief notice or report publication announcement.
2021-01-21 Chinese
关于参与投资设立成都华西细胞治疗研究院有限公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company about its investment in establishing a new company (成都华西细胞治疗研究院有限公司). It details the investment amount, shareholders, business scope, and risks associated with the investment. There is no financial data, no mention of quarterly or annual results, no audit information, no management changes, no voting results, no legal proceedings, no merger or acquisition activity, and no regulatory certifications. The document is a formal announcement of a capital investment and establishment of a subsidiary or related company. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is 3754 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2021-01-20 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.